GlassScriptPhysician profile
Lise Huddleston
NPI 1962822965
$5,375.36
in general payments reported to CMS, 2019-2025
38 companies · $867 in 2025
The $867 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $265 · 2021: $1,064 · 2022: $1,387 · 2023: $1,148 · 2024: $430 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,444.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.99 | 2019-2024 | |
| Daiichi Sankyo INC. | $595.97 | 2021-2024 | Injectafer |
| Intuitive Surgical, INC. | $296.25 | 2021-2023 | Da Vinci Surgical System |
| Pfizer INC. | $272.51 | 2019-2025 | |
| Shield Therapeutics INC | $264.99 | 2022-2025 | Accrufer |
| Lupin INC. | $260.16 | 2019-2021 | |
| Sage Therapeutics, LLC | $226.80 | 2022-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $203.01 | 2021-2025 | Myosure Tissue Removal Device, Novasure, Aptima |
| Avion Pharmaceuticals | $192.79 | 2021-2023 | Balcoltra |
| Astellas Pharma US INC | $189.17 | 2023-2025 | Veozah |
| Evofem Biosciences, INC. | $181.73 | 2021-2023 | Phexxi |
| Bayer Healthcare Pharmaceuticals INC. | $180.24 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $170.11 | 2022-2025 | |
| Aspira Women'S Health INC | $160.15 | 2021-2022 | |
| Organon LLC | $144.68 | 2021-2025 | Nexplanon |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $113.92 | 2022-2025 | Arista |
| Minerva Surgical, INC | $111.38 | 2025 | |
| Merz North America, INC. | $97.35 | 2022 | |
| Sumitomo Pharma America, INC. | $95.13 | 2023-2024 | Myfembree |
| Davol INC. | $91.68 | 2021-2024 | Arista Ah Flexitip |
| Coloplast Corp | $87.17 | 2022-2024 | |
| Amgen INC. | $83.14 | 2022-2023 | Evenity, Prolia |
| Exeltis, USA INC. | $64.95 | 2021-2025 | Slynd |
| Myriad Women'S Health, INC. | $57.46 | 2023 | Myrisk |
| Lilly USA, LLC | $54.06 | 2025 | Zepbound, Mounjaro |
| Coopersurgical, INC. | $51.76 | 2021-2025 | Mara Console, Ally II Ups |
| Novo Nordisk INC | $43.40 | 2023 | Wegovy |
| Ethicon US, LLC | $41.18 | 2021-2022 | |
| Smith+Nephew, INC. | $36.64 | 2022-2025 | Pico |
| Scynexis, INC. | $33.05 | 2022 | |
| Dexcom, INC. | $29.09 | 2025 | Dexcom G6 Transmitter |
| Innovation Technologies INC | $22.32 | 2025 | Irrisept |
| Axonics, INC. | $21.78 | 2023 | Bulkamid |
| Axsome Therapeutics, INC. | $20.45 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.90 | 2025 | |
| Myovant Sciences INC. | $14.77 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.67 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lise Huddleston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.